NCT03101748: Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

NCT03101748
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Inflammatory breast cancer
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 21 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have HER2+ (IBC or non-IBC) breast cancer to participate in Phase 1b; Patients must have IBC that is NOT TNBC to participate in Phase 2- HER2+ IBC patients are eligible for Cohort 1 & HR+ & HER2-negative IBC patients are eligible for Cohort 2
Exclusions: 
https://ClinicalTrials.gov/show/NCT03101748

Comments are closed.

Up ↑